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Abstract 
Purpose 
The purpose of this study was to determine whether the presence of upper extremity 
chemotherapy-induced peripheral neuropathy (CIPN) symptoms (burning, pins/needles, 
numbness, pain and skin crawls) varied according to age (< 45 years) or (55-70 years); and to 
examine age group differences in upper extremity CIPN symptom distress. 
Methods 
A secondary analysis of younger (n=505) and older (n=622) breast cancer survivors. Inclusion 
criteria were age < 45 years of age or 55-70 years of age; 3-8 years post-diagnosis; having 
received the chemotherapy regimen of Taxol®, Adriamycin®, and Cytoxan®; and without 
recurrence. The Symptom Survivor Checklist was used to assess presence and distress of upper 
extremity CIPN symptoms. Analyses explored whether age group predicted CIPN symptom 
presence and distress, while controlling for sociodemographic and medical variables.  
Results  
Older BCS reported fewer pins/needles, numbness and pain symptoms (OR .623-.751). Heart 
disease (OR 1.6-1.7) and progesterone-negative breast cancer (OR .663) also were significantly 
differ by age groups; both age 
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 associated with CIPN symptoms. Symptom distress ratings did not 
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groups indicated distress from CIPN symptoms, with 25% or more reporting as “moderately” or 
as “quite a bit” of distress. 
Conclusion 
Younger BCS reported more upper extremity CIPN symptoms. BCS in both groups continued to 
report bothersome CIPN symptoms years post-treatment. Findings from this study will assist 
clinicians in identifying BCS at higher risk for upper-extremity CIPN and inform the 
development of appropriate tailored interventions to mitigate these symptoms and facilitate 

























Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most prevalent, 
persistent, and disruptive symptoms associated with common antineoplastic treatments (e.g., 
taxanes) for breast cancer.1-5 Approximately two-thirds of breast cancer survivors (BCS) report 
symptoms of CIPN during cancer treatment, 6 with as many as 42% reporting lingering 
symptoms for up to 3 years post treatment.2, 7-10 Symptoms of CIPN include sensations of 
burning, pins/needles, numbness,1, 5, 9 pain1, 5  and/or skin crawls affecting the hands and/or feet.1, 
4, 5, 11-13 Although treatments have improved, the continued reliance on taxanes (e.g., Paclitaxel) 
and other neurotoxic agents to treat breast cancer has contributed to serious, and at times, 
permanent changes that significantly interfere with survivors’ daily functioning.5, 7, 9, 11, 12 
The onset of CIPN in BCS has been associated with sociodemographic (age 7, 11, 14, 15 
race, 2, 9, 15 income,16  education,16 and alcohol consumption)16 and medical characteristics 
(comorbidities,5, 11, 16 hormone status,2 tumor size,10 body mass index,2, 9, 15 number of positive 
nodes,10 and years from diagnosis.17, 18 Age in particular may be an important risk factor in both 
CIPN symptom presence and distress.7, 11, 14, 15 While several studies have found a higher 
prevalence and longer duration of CIPN symptoms in older BCS (60 years of age and older),2, 7, 
11, 14-16 others have found a higher prevalence of CIPN symptoms in younger BCS. 2, 19 Yet still, 
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some studies found no association between age and the presence of CIPN symptoms. 20, 21 Most 
of these studies have concentrated exclusively on the lower extremities, with little focus on upper 
extremity CIPN symptoms. Determining the impact of upper extremity CIPN symptoms is 
important to study as fine motor movements can be impaired, 22 potentially interfering with the 
ability of BCS to perform daily activities. Understanding age-related differences in the presence 
and impact of upper extremity (shoulder, arms, hands and fingers) CIPN symptoms is important, 
given that symptoms may differentially affect independence and quality of life. 5, 17, 19 While 
lower extremity CIPN may be more distressing for older BCS (e.g., concerns about increased 
falls), upper extremity CIPN may be more distressing for younger BCS (e.g., concerns about 
managing work and family responsibilities).  
The purpose of this study was to examine upper extremity CIPN symptoms among BCS 
according to age group (younger versus older BCS). The aims of this study were twofold. Aim 1 
sought to determine whether the presence of upper extremity CIPN symptoms (burning, 
pins/needles, numbness, pain and skin crawls) varied according to age group. Aim 2 sought to 
examine age group differences in upper extremity CIPN symptom distress. This information will 
be particularly useful for clinicians and researchers challenged in the care of long-term and 
troubling symptoms of CIPN. Findings from this study will assist with identifying BCS at higher 
risk for CIPN and inform the development of tailored interventions to mitigate these symptoms. 
Methods 
Study Design and Sample 
This study is a secondary analysis of 1,127 BCS (younger and older) using data from a 
cross-sectional quality of life study that included several self-reported measures for common 
symptoms experienced by BCS. Details of the parent study have been described previously.23 
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Briefly, BCS were eligible for the if they were 1) 45 years old or younger (younger BCS) or 55-
70 years old (older BCS) at diagnosis; 2) 3-8 years post-diagnosis without recurrence; and 3) 
received a chemotherapy regimen that included Paclitaxel, Doxorubicin, and  Cyclophosphamide 
as part of their initial breast cancer treatment. BCS 46-54 years of age were excluded to avoid the 
potential confounding peri-menopausal timeframe. The study was approved by the coordinating 
university’s institutional review board.  
Measures 
Sociodemographic variables (independent variables). Sociodemographic variables, 
including age, race, income, education, and alcohol consumption were self-reported. Age was 
coded as a dichotomous variable of younger (45 years or younger) and older (55-70 years) which 
was consistent with the targeted enrollment groups, as it is less common for BCS over 70 years 
of age to receive this treatment regimen. Race was coded as a categorical variable (white or non-
white), income was coded as a dichotomous variable (< $75,000 or ≥ 75, 000) and education was 
coded as a continuous variable for years of education. Alcohol consumption was queried by 
asking, “On those days that you drink alcoholic beverages, about how many do you usually 
have?” Response options were > 5 drinks, 3-5 drinks, 1-2 drinks, and I do not drink (none). For 
this study, the alcohol consumption variable was recoded into categories of ≥ 3 drinks per day, 1-
2 drinks per day, or none. 
Medical variables (independent variables). Medical information was collected via self-
report from BCS and included comorbidities (heart disease, hypertension and diabetes), hormone 
status, tumor size, body mass index (BMI; calculated from height and weight), number of 
positive nodes, and years from diagnosis. Researchers reviewed medical records to verify 
patient-reported information.  
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Chemotherapy-induced peripheral neuropathy symptoms (dependent variables). The 
Symptom Survivor Checklist was developed for this study based on review of CIPN literature. 1, 
4, 5, 11-13 The Symptom Survivor Checklist is a 12-item scale that assesses five common upper 
extremity CIPN symptoms on the affected side, including burning, pins/needles, numbness, pain 
and skin crawls. BCS were asked if the symptoms were present (yes/no). If present, then BCS 
rated the extent to which they were bothered or distressed by symptoms on a 5-point ordinal 
scale (0 = not at all; 1= slightly; 2 = moderately; 3 = quite a bit; 4 = extremely). Higher scores 
were indicative of greater symptom distress. Cronbach’s alpha for this scale in our study was 
0.78. 
Data analysis. Data analysis was conducted using SPSS version 25.0 (IBM Corp., 
Armonk, NY) and significance was set at p = .05. Two-tailed tests were used for all comparisons. 
Prior to the analysis, Shapiro-Wilks tests were used to test for normality of the data. Descriptive 
statistics were used to summarize the distributions of sociodemographic and medical variables. 
To examine age group differences in sociodemographic and medical characteristics, we used 
Pearson chi-square tests for categorical variables (race, income, marital status, comorbidities, 
hormone status, alcohol consumption) and independent t-tests for continuous variables (years of 
education, BMI, years from diagnosis, number of positive nodes, tumor size).  
For aim 1, we first conducted five separate Pearson chi-square tests to determine if there 
was a significant association between age group and the presence of each of the five upper-
extremity CIPN symptoms (burning, pins/needles, numbness, pain and skin crawls). Three 
significant symptoms were analyzed in a series of separate binary logistic regression analyses to 
determine whether age group was associated with the presence of the symptoms, while 
controlling for sociodemographic (age, race, income, education, and alcohol consumption) and 
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medical (heart disease, hypertension and diabetes, hormone status, tumor size, BMI, number of 
positive nodes, and years from diagnosis) variables that theoretically could influence CIPN. In 
the regression model, each symptom was entered as a dependent variable; age was an 
independent variable along with other sociodemographic and medical covariates. Using a 
backward deletion approach, statistically non-significant sociodemographic and medical 
characteristics were removed until the final model was achieved.  
For aim 2, Mann Whitney U tests were conducted to examine age group differences in 
symptom distress. Participants who did not report any CIPN symptoms were removed from the 
Mann Whitney U analysis. If significant, backward deletion ordinal logistic regression analyses 
would have been conducted to determine if age group predicted symptom distress, while 
controlling for sociodemographic and medical characteristics. 
Results 
Sample Characteristics 
Sociodemographic and medical characteristics of younger (n = 505) and older (n = 622) 
BCS are shown in Table 1. On average, BCS were 6 years post treatment. Compared to older 
BCS, younger BCS had significantly higher incomes, were more likely to be married, had fewer 
comorbidities, consumed more alcohol, and had more years of education.  
Aim 1. Presence of CIPN Symptoms  
Table 2 shows the Chi Square results for the presence of upper extremity CIPN 
symptoms for the total sample and by age group. Age group (younger age) was significantly 
associated with three CIPN symptoms, pins/needles (p =.021), numbness (p <.001), and pain 
(<.001).   
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Results of logistic regression analyses are summarized in Table 3. Age significantly 
predicted the presence of pins/needles, numbness and pain symptoms. Older BCS had lower 
odds of reporting upper extremity pins/needles, numbness and pain symptoms compared to 
younger BCS (OR .623-.751). Comorbid heart disease also was a significant predictor of these 
three upper-extremity CIPN symptoms. BCS with heart disease were 1.6-1.7 times more likely to 
report pins/needles, numbness and pain symptoms. Additionally, hormone status predicted the 
presence of the pins/needles symptom. Those with positive progesterone receptor status (PR+) 
had lower odds (OR .663) of experiencing the pins/needles symptom. While statistically 
significant, the variation (R2) in the dependent variable based on our models ranged from 2.3-
2.9%, demonstrating a small but reliable relationship between age and upper extremity CIPN 
symptoms (pins/needles, numbness, pain).   
Aim 2. Symptom Distress  
Table 4 shows the level of distress associated with CIPN symptoms by age group. 
Distress scores ranged from 1 (slightly) to 3 (quite a bit), with the typical score (i.e., median) 
indicating BCS were slightly or moderately distressed. It should be noted that 2 or 3, depending 
on the symptom, was not only the maximum score, but also the 75th percentile, indicating that 
25% of BCS perceived “moderately” or “quite a bit” of distress for each symptom.  Mann 
Whitney U tests showed no significant age group differences in upper extremity CIPN symptom 
distress. Given that there were no statistically significant age group differences in symptom 
distress scores, ordinal logistic regression was not conducted.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
Discussion 
The purpose of this study was to describe the presence and distress level of upper 
extremity CIPN symptoms in BCS three or more years post-treatment. The findings of this study 
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offer several key insights. First, our findings add to the literature showing that younger BCS 
report the presence of upper extremity CIPN symptoms more often than older BCS. Second, 
comorbid heart disease and hormone status were risk factors for upper extremity CIPN 
symptoms. Third, both younger and older BCS continued to report upper extremity CIPN 
symptoms as distressing several years post-treatment.  
Aim 1. Presence of CIPN Symptoms  
While factors such as treatment duration and the intensity of taxane exposure BCS 
receive during treatment are known factors for developing chronic CIPN,10-12 the role of age on 
these symptoms is less clear. In our study, we found younger BCS were more likely to report 
upper extremity CIPN symptoms of pins/needles, numbness and pain compared to their older 
counterparts. This finding is consistent with other studies that have shown younger BCS may be 
at higher risk of developing CIPN symptoms.2, 19 Ali and colleagues found younger BCS had a 
higher lower risk of CIPN than younger BCS. However, the researchers did not discuss how 
CIPN was defined by location, limiting the ability to generalize the finding to other BCS 
populations.2 Although underlying mechanisms contributing to age-related differences in CIPN 
symptoms are not clear, one possible explanation is that unlike younger BCS, older BCS may 
have pre-existing neuropathy and/or other neurodegenerative loss from comorbid conditions that 
lessen their perception of these symptoms.  
In contrast to our findings, other studies have shown that older BCS are at increased risk 
for CIPN symptoms. Hershman and colleagues linked clinical trial data with Medicare claims 
and found older age to be the only demographic factor associated with the presence of upper and 
lower extremity CIPN symptoms.13 However, the mean age of the sample was older (73 years of 
age), which may have influenced the study findings, additionally the lack of access to baseline 
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neurologic status, to determine if symptoms of neuropathy were pre-existing or new onset; may 
have resulted in higher reporting of symptom presence impacting the results of the study.   
 Similarly, Lichtman and colleagues examined neurotoxicity (neurosensory, neuromotor, 
neurocortical or neurocerebellar) symptoms among BCS (N =1048) in three age categories (< 55 
years, 55-64 years and ≥65 years).24 Compared to those in the younger age categories, women  ≥ 
65 years of age (n=272) reported earlier onset and the presence of neurotoxicity with first and 
second-line chemotherapy treatments.24  However, the focus of the study was specific to 
neurotoxicity; which may influence neuropathy but cannot be directly extrapolated to CIPN 
symptoms.   
Other researchers have found no association between age and CIPN symptoms. Schneider 
and colleagues studied BCS (n = 4,554) in three age categories (≤45, 46-65, and > 65 years) all 
receiving adjuvant taxane therapy.25Although they found CIPN symptoms in upper and lower 
extremities were  common complications of treatment, age was not an associated factor. 25  
However, the researchers indicated that a lack of uniform and validated CIPN assessments may 
have decreased the reliability of the study findings. More research is needed to assess if upper 
extremity CIPN symptoms differ by age among BCS. 
Although diabetes has been noted as a risk factor for CIPN in BCS,13 we did not find 
diabetes to be associated with upper extremity CIPN in our study. This finding may be related to 
the typical presentation of CIPN symptoms in the lower extremities in people with diabetes 26 
whereas our study focused on upper extremity symptoms. Additionally, the number of BCS with 
comorbid diabetes (n = 121) in this study was low.  An important finding from our study was 
that BCS with comorbid heart disease were more likely to report the presence of pins/needles, 
numbness and pain symptoms in the years following treatment. Heart disease, hypertension, and 
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diabetes, the most frequently documented comorbidities 27,  28-33 in BCS, are all associated with 
an increased risk of CIPN.6,  30, 31 The BCS in our study received the same therapeutic regimen 
that included two of the most common cardiotoxic chemotherapies (Doxorubicin, and 
Paclitaxel). Because we examined heart disease broadly, we were not able to identify specific 
cardiac pathologies, nor determine if they occurred prior to or after cancer diagnosis and 
treatment, limiting our ability to determine if cardiovascular disease is a direct risk factor for 
CIPN, especially in the upper extremities. The influence of comorbid heart disease on CIPN 
symptoms among BCS has not been well studied. As BCS are living longer, the role of comorbid 
conditions on CIPN symptoms is important to understand and warrants further research. 
Clinicians should assess for the presence of CIPN symptoms in BCS with a history of heart 
disease.  
Finally, although estrogen status did not predict upper extremity CIPN symptoms, 
progesterone status did. Specifically, BCS who were PR+ were less likely to report sensations of 
pins/needles in the years following treatment than BCS who were PR-.  Our findings are 
consistent with other researchers who found that PR- status was associated with an increased risk 
of developing CIPN.9 Studies have suggested that progesterone may have neuroprotective effects 
on the central and peripheral nervous systems by promoting repair of myelin.33, 34Although, the 
degree to which this may reduce the severity of taxane-induced CIPN is unclear. More research 
is needed to understand the role of hormone status on the symptoms of CIPN.  
Aim 2. Symptom Distress  
Results of our study found that even an average of six years post-treatment, BCS reported 
being distressed by their CIPN symptoms. However, although younger BCS were more likely 
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than older BCS to report upper extremity CIPN symptoms; we found no difference in distress 
levels with both younger and older BCS.   
Studies examining differences by BCS age on symptom distress from upper extremity 
CIPN, are lacking. We found two studies that assessed CIPN symptom distress by age. Tanabe 
and colleagues found CIPN symptoms were more severe and persistent among older (≥ 60 years 
old) BCS.14 However, the authors assessed CIPN symptoms in combination of upper and lower 
extremities, and did not differentiate symptom distress by location of  upper or lower extremity. 
Wong and colleagues assessed age-related differences in a both upper and lower extremity CIPN 
symptoms of cancer survivors (n = 425), and found younger cancer survivors reported more 
severe pain and more interference in activity from CIPN symptoms when compared to older 
cancer survivors.19 However, the study included heterogenous cancer diagnoses as well as 
survivors with metastatic disease which may have influenced the findings. Other studies have 
shown younger survivors with CIPN report more difficulty with general activities, work, and 
other components of quality of life,19, 35, 36  an important finding given that they have not 
experienced nor adapted to the age-related losses that commonly occur with aging.19 
The lack of association between age and CIPN distress we observed in the present study 
may have been a result of our choice of measure, which only assessed upper extremity CIPN 
symptoms. Future research should assess the symptom experience of upper and lower CIPN 
symptoms individually as well as collectively. Assessing upper and lower extremity function 
separately in BCS may provide helpful information as it relates to the differential impact of 
CIPN on function, and daily activities.  
It is important to note, although we did not observe an age specific difference in the level 
of distress from upper extremity CIPN symptoms, both younger and older BCS still indicated  
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distress from these symptoms even years post treatment; with 25% or more reporting 
“moderately” or as “quite a bit” of distress, depending on the particular symptom. This finding 
supports other research that illustrates the lingering long-term impact of CIPN symptoms 
experienced by BCS. Future research should consider examining upper extremity CIPN 
symptoms in younger and older BCS longitudinally across the trajectory of cancer treatment into 
survivorship. 
This study had several strengths. This study contributes to a growing body of literature by 
identifying age-related differences in three upper extremity CIPN symptoms. To our knowledge, 
this is one of the first studies to evaluate the impact of age and medical variables on specific 
upper extremity CIPN symptoms in BCS, and one of the first to evaluate this in a cohort > 3 
years post treatment. Results from our analysis were drawn from a large, nationally 
representative sample of BCS that received one of the most common taxane-based regimens (a 
primary driver of CIPN in BCS), increasing the generalizability of the findings. The study 
included a 10-year separation between younger and older BCS, reducing variation in the sample. 
Given our findings that younger BCS are at risk, future research should explore the development 
and testing of age appropriate interventions to restore function, reduce distress, and improve 
quality of life.  
Findings from this study also need to be considered in the context of several limitations. 
First, because of the cross-sectional study design, neurological diagnostic testing was not 
available, which limited the ability to identify baseline CIPN symptoms or determine if the 
symptoms evolved over time. Second, the upper age limit of older BCS in our study was 70 
years of age, whereas other studies included much older subjects 65 or more years of age which 
may have influenced these findings. Third, we did not have access to information on cumulative 
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exposure to taxanes for participants, which could have an impact on CIPN symptoms. Fourth, 
because African American women, who have a 2- to 3-fold higher risk of taxane-induced CIPN 
than Caucasian women,11, 13 were not well represented in this study, this limits generalizability to 
other race/ethnicities. Finally, although the Survivor Symptom Checklist demonstrated an 
acceptable Chronbach alpha, additional validation of the tool is warranted. Despite these 
limitations, the findings from this study add to the body of knowledge as it relates to the presence 
and distress of upper extremity CIPN symptoms from the younger and older BCS’s perspective, 
which is an understudied area.   
Implications for Practice 
The information from this study will be particularly useful for clinicians and researchers 
challenged in the care of long-term and troubling CIPN symptoms. We found upper extremity 
CIPN symptoms can be distressing for BCS years post-treatment. CIPN symptoms are typically 
assessed in combination with lower extremity symptoms at the onset and intermittently during 
active treatment for cancer. Our findings elucidate the need for ongoing assessment and 
monitoring of upper extremity CIPN symptoms in BCS throughout the cancer trajectory well 
into survivorship. These assessments can facilitate referrals to rehabilitative programs to 
implement age-specific rehabilitative interventions geared towards maximizing safety and 
physical function improving overall quality of life for BCS.  
Our findings have integral implications for occupational and rehabilitative staff when 
developing treatment plans aimed towards improving safety and functional performance for 
long-term BCS in survivorship programs. Of particular importance is our finding that younger 
BCS — for whom work is likely to be a critical issue — are more likely than older BCS to report 
pain, tingling, and numbness in their upper extremities. Although research specific to upper 
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extremity CIPN symptoms in BCS is nominal, several studies have implicated CIPN 
(upper/lower combined) symptoms (including the presence, number, type and duration of 
symptoms) with difficulty performing work-related tasks.36-38  Successful rehabilitation efforts 
can facilitate strategies to increase participation in work, earlier return to work and improve 
activities of daily living, and overall quality of life.  
Future research should consider examining upper extremity CIPN symptoms 
longitudinally in a more diverse sample of BCS across the trajectory of cancer treatment into 
survivorship. Additionally, research testing age-appropriate tailored interventions towards 
mitigating these symptoms, can thereby facilitate restoration to age-related baseline functional 
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Table 1. Comparison of Sociodemographic and Medical Characteristics of Younger and Older 
Breast Cancer Survivors 
Variables Younger 
Survivors 
< 45 years 
(N = 505) 
Older  
Survivors 
≥ 55 years 
(N = 622) 
p-value 
                     N (%)  
Race 
     White 
      Non-White 
 








     < 75, 000 









Marital status  
     Married 
     Non-Married 













     Heart disease: Yes 
     Hypertension: Yes 
































     Estrogen: Yes  
     Progesterone: Yes 










      3 or more 
 









Mean (standard deviation) 
Years of education   14.8 (2.6) 14.1 (2.7) <.001 
Body mass index 27.8 (6.1) 28.4 (5.9) .102 
Years from diagnosis 5.9 (1.5) 6 (1.5) .336 
Number of positive 
nodes 
1.5 (2.6) 1.7 (3.2) .272 
Tumor size (cm)  2 (1.4) 1.9 (1.3) .394 
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Table 2. Presence of Peripheral Neuropathy Symptoms by Total Sample and between Younger 
and Older Breast Cancer Survivors (Chi Square). 
Symptom All 
N = 1127 
Younger 
N = 505 
 Older 
N = 622 
 
p-value 
 N (%) N (%) N (%)  
Burning 119 (9) 60 (12) 59 (10) .284 
Pins/needles 368 (33) 185 (37) 183 (30) .021 
Numbness 442 (39) 232 (46) 210 (34) <.001 
Skin crawls 109 (10) 58 (11) 51 (8) .085 

















Table 3. Predictors of Symptom Presence (yes/no) among Breast Cancer Survivors (Logistic 
Regression) 
Pins/needles, N= 368, X2 = 4.92,  DF (4), R2 = .029, p <.001 
Variable Standard  
Beta 
SE  Beta p-value Odds Ratio 95% CI 
Older vs younger 
BCS 
-.286 .144 .048 .751 .566  .997 
Heart disease 
(present vs not 
present) 




-.412 .163 .005 .663 .495  .886 
Numbness, N = 442, X2 =  5.056, DF (4), R2 = .023, p = .001 
Variable Standard 
Beta 
SE Beta p-value Odds Ratio Confidence 
interval 
Older vs younger 
BCS 
-.449 .137  .001 .638 .488 .835 
Heart disease 
(present vs not 
present) 
.466 .218   .032 1.59 1.04, 2.44 





SE Beta p-value Odds Ratio Confidence 
interval 
Older vs younger 
BCS 
-.474 .145  .001 .623 .469 .827 
Heart disease 
(present vs not 
present) 



















Table 4.  Comparison of Symptom Distress by Age Groups (Mann Whitney U) 











N = 290 
0-4 (1-3) N = 120 N = 170  
2.0 (1, 2) 2.0 (1, 3) .521 
Pins/needles 
N = 347 
0-4 (1-2) N = 173 N = 174  
1.0 (1, 2) 1.0 (1, 2) .992 
Numbness 
N = 376 
0-4 (1-3) 
 
N = 193 N = 183  
2.0 (1, 3) 2.0 (1, 2) .117 
Pain 
N = 332 
0-4 (1-2) N = 181 N = 151  
1.0 (1, 2) 1.0 (1, 2) .330 
Skin Crawls 
N = 107 
0-4 (1-3) N = 56 N = 51  
2.0 (1, 2) 2.0 (1, 3) .885 
 
